Nurix Therapeutics, Inc.
Financial highlights
| Metric | FY 11/30/25 | FY 11/30/24 | FY 11/30/23 | FY 11/30/22 | FY 11/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $84.0 | $54.5 | $77.0 | $38.6 | $29.8 |
| Operating income | -$285.7 | -$213.0 | -$155.1 | -$183.9 | -$117.9 |
| Net income | -$264.5 | -$193.6 | -$143.9 | -$180.4 | -$117.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$263.5 | -$181.9 | -$89.8 | -$172.1 | -$90.0 |
| Share repurchases | — | — | — | — | $0.0 |
Shares outstanding 103.8M · Free float 93.0%
Annual filing data through FY ended November 30, 2025; float as of September 30, 2026.